Some effects of risperidone and quetiapine on growth parameters and hormone levels in young pigtail macaques

Journal of Child and Adolescent Psychopharmacology

Volumn 20, Issue 6, 2010, Pages 489-493

  Sackett, Gene ^a   Unis, Alan ^b,c   Crouthamel, Brenda ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c Kootenai Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; THYROID HORMONE;

ANIMAL EXPERIMENT; BODY GROWTH; BODY WEIGHT; BONE DENSITY; BONE GROWTH; BONE MINERALIZATION; CONFERENCE PAPER; DRUG EFFECT; MACACA NEMESTRINA; MALE; NONHUMAN; PROLACTIN BLOOD LEVEL; THYROID HORMONE BLOOD LEVEL;

AGE FACTORS; ANIMALS; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; BONE AND BONES; BONE DENSITY; CHILD; CHILD, PRESCHOOL; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MACACA NEMESTRINA; MALE; MODELS, ANIMAL; PROLACTIN; RANDOM ALLOCATION; RISPERIDONE; THYROID HORMONES;

EID: 78650658495     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2010.0018     Document Type: Conference Paper

References (12)

1. Abraham G, Paing W, Kaminski J, Joseph A, Kohegyi E, Josiassen R: Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: A prospective study. Am J Psychiat 160:1618-1620, 2003.
2. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765-1773, 2009.
3. Diamond A: The development and neural bases of memory functions as indexed by the AB and delayed response tasks in human infants and infant monkeys. Ann NY Acad Sci 608:267-317, 2006.
4. Findling R, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C: Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64:1362-1369, 2003.
5. Fraguas D, Merchan-Naranjo J, Laita P, Parellada, M, Moreno D, Ruiz-Sancho A, Cifuentes A, Giraldez M, Atango C: Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 69:1166-1175, 2008.
6. Haas M, Unis A, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF: A 6-week, randomized, bouble-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 19:611-621, 2009.
7. Jensen P, Buitelaar J, Pandina G, Binder C, Haas M: Management of psychiatric disorders in children and adolescents with atypical an-tipsychotics: A systematic review of published clinical trials. Child Adolesc Psychiatr 16:104-120, 2007.
8. Olfson, Blanco, Iiu L, Moreno C, Laje G: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63:679-85, 2006.
9. Ruppenthal G, Sackett G: Research Protocol & Technician's Manual, IPRL, 2nd ed, Washington: University of Washington; 1992.
10. Sikich L, Frazier JA, McClellan J, Findling, RL, Vitiello B, et al.: Double-Blind comparison of first- and second generation anti-psychotics in early-onset shcizophrenia and schizo-affective disorder: Findings from the treatment of early onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165:1420- 1431, 2008.
11. Trugay A, Binder C, Snyder R, Fisman S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:e34, 2002.
12. Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C: Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. Eur Neuropscho-pharmacol 19:629-635, 2009.